Updates on immunotherapy for colorectal cancer

被引：126

作者：

Kalyan, Aparna ^{[1
,2
]}

Kircher, Sheetal ^{[2
]}

Shah, Hiral ^{[1
,2
]}

Mulcahy, Mary ^{[2
]}

Benson, Al ^{[2
]}

机构：

[1] Feinberg Sch Med, Div Hematol & Oncol, Dev Therapeut Program, Chicago, IL USA

[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

来源：

JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2018年 / 9卷 / 01期

关键词：

Colorectal cancer (CRC); immunotherapy; microsatellite instability (MSI); vaccine therapy; ACTIVE SPECIFIC IMMUNOTHERAPY; PHASE-I; COLON-CANCER; CARCINOEMBRYONIC ANTIGEN; LIVER METASTASES; DENDRITIC CELLS; TUMOR-CELLS; PEPTIDE; VACCINE; VIRUS;

D O I：

10.21037/jgo.2018.01.17

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite significant advances in standard of care therapies, the 5-year survival rate for metastatic colorectal cancer (CRC) remains around 12%. Immunotherapy has not provided the stellar advances in colorectal cancer that has been seen in other malignancies. Immunotherapy appears to play a pivotal role in microsatellite unstable CRC tumors where the response rates are profound. These results have led to FDA approval of pembrolizumab for MSI-H CRC tumors. Additional research into several new immune agents including IDO inhibitors, vaccine therapy and combinatorial agents are being evaluated for CRC. This review will provide an overview of the approaches currently being investigated.

引用

页码：160 / 169

页数：10

共 78 条

[11] Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients [J].

Caballero-Banos, Miguel ;

Benitez-Ribas, Daniel ;

Tabera, Jaime ;

Varea, Sara ;

Vilana, Ramon ;

Bianchi, Luis ;

Ramon Ayuso, Juan ;

Pages, Mario ;

Carrera, Gemma ;

Cuatrecasas, Miriam ;

Martin-Richard, Marta ;

Cid, Joan ;

Lozano, Miguel ;

Castells, Antoni ;

Garcia-Albeniz, Xabier ;

Maurel, Joan ;

Vilella, Ramon .

EUROPEAN JOURNAL OF CANCER, 2016, 64 :167-174

[12] Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer [J].

Clarke, Ellen ;

Coffin, Robert .

IMMUNOTHERAPY, 2016, 8 (02) :103-106

[13] Control of Immunity by the TNFR-Related Molecule OX40 (CD134) [J].

Croft, Michael .

ANNUAL REVIEW OF IMMUNOLOGY, VOL 28, 2010, 28 :57-78

[14] OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients [J].

Curti, Brendan D. ;

Kovacsovics-Bankowski, Magdalena ;

Morris, Nicholas ;

Walker, Edwin ;

Chisholm, Lana ;

Floyd, Kevin ;

Walker, Joshua ;

Gonzalez, Iliana ;

Meeuwsen, Tanisha ;

Fox, Bernard A. ;

Moudgil, Tarsem ;

Miller, William ;

Haley, Daniel ;

Coffey, Todd ;

Fisher, Brenda ;

Delanty-Miller, Laurie ;

Rymarchyk, Nicole ;

Kelly, Tracy ;

Crocenzi, Todd ;

Bernstein, Eric ;

Sanborn, Rachel ;

Urba, Walter J. ;

Weinberg, Andrew D. .

CANCER RESEARCH, 2013, 73 (24) :7189-7198

[15] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].

Fehrenbacher, Louis ;

Spira, Alexander ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

Vansteenkiste, Johan ;

Mazieres, Julien ;

Park, Keunchil ;

Smith, David ;

Artal-Cortes, Angel ;

Lewanski, Conrad ;

Braiteh, Fadi ;

Waterkamp, Daniel ;

He, Pei ;

Zou, Wei ;

Chen, Daniel S. ;

Yi, Jing ;

Sandler, Alan ;

Rittmeyer, Achim .

LANCET, 2016, 387 (10030) :1837-1846

[16] Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy [J].

Fong, L ;

Hou, YF ;

Rivas, A ;

Benike, C ;

Yuen, A ;

Fisher, GA ;

Davis, MM ;

Engleman, EG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8809-8814

[17] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].

Garon, Edward B. ;

Rizvi, Naiyer A. ;

Hui, Rina ;

Leighl, Natasha ;

Balmanoukian, Ani S. ;

Eder, Joseph Paul ;

Patnaik, Amita ;

Aggarwal, Charu ;

Gubens, Matthew ;

Horn, Leora ;

Carcereny, Enric ;

Ahn, Myung-Ju ;

Felip, Enriqueta ;

Lee, Jong-Seok ;

Hellmann, Matthew D. ;

Hamid, Omid ;

Goldman, Jonathan W. ;

Soria, Jean-Charles ;

Dolled-Filhart, Marisa ;

Rutledge, Ruth Z. ;

Zhang, Jin ;

Lunceford, Jared K. ;

Rangwala, Reshma ;

Lubiniecki, Gregory M. ;

Roach, Charlotte ;

Emancipator, Kenneth ;

Gandhi, Leena .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028

[18] Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver [J].

Geevarghese, Sunil K. ;

Geller, David A. ;

de Haan, Hans A. ;

Hoerer, Markus ;

Knoll, Anette E. ;

Mescheder, Axel ;

Nemunaitis, John ;

Reid, Tony R. ;

Sze, Daniel Y. ;

Tanabe, Kenneth K. ;

Tawfik, Hoda .

HUMAN GENE THERAPY, 2010, 21 (09) :1119-1128

[19] Phenotype of microsatellite unstable colorectal carcinomas - Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability [J].

Greenson, JK ;

Bonner, JD ;

Ben-Yzhak, O ;

Cohen, HI ;

Miselevich, I ;

Resnick, MB ;

Trougouboff, P ;

Tomsho, LD ;

Kim, E ;

Low, M ;

Almog, R ;

Rennert, G ;

Gruber, SB .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (05) :563-570

[20] Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer [J].

Gryfe, R ;

Kim, H ;

Hsieh, ETK ;

Aronson, MD ;

Holowaty, EJ ;

Bull, SB ;

Redston, M ;

Gallinger, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (02) :69-77

← 1 2 3 4 5 6 7 8 →